Echocardiographic and clinical effects of two sedative doses of Dexmedetomidine in healthy horses.
Authors: Roustaei Ali, Masoudifard Majid, Azari Omid, Keshipour Hadi, Koohestani Omid
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Dexmedetomidine's Cardiac Effects in Horses Dexmedetomidine (DEX) is increasingly used as a sedative in equine practice, yet its effects on cardiac structure and function remained poorly characterised in horses until now. Six healthy mares received two intravenous doses of DEX—a low dose of 3.5 µg/kg and a high dose of 7 µg/kg—with echocardiographic measurements taken before and after sedation to evaluate changes in cardiac dimensions, valve function, and blood flow parameters. Both doses produced measurable structural changes: the pulmonary artery and left atrium dilated at end-systole, the aortic valve diameter increased, and both left and right ventricular internal diameters enlarged at end-systole, whilst pulmonary artery blood velocity and pressure gradients decreased significantly. Reassuringly, neither dose affected overall cardiac function measurements or valvular regurgitation, suggesting these dimensional changes represent haemodynamic shifts rather than functional compromise. For practitioners using DEX sedation in clinical settings, these findings indicate the drug produces expected alpha-2 agonist effects on cardiac physiology that appear benign in healthy horses, though careful monitoring remains prudent in animals with pre-existing cardiac disease or those requiring prolonged sedation.
Read the full abstract on PubMed
Practical Takeaways
- •Dexmedetomidine sedation causes measurable changes in cardiac dimensions and pulmonary hemodynamics in horses; clinicians should be aware these are expected physiological responses to the drug rather than pathological changes
- •The echocardiographic effects are similar at both low (3.5 µg/kg) and high (7 µg/kg) sedative doses, suggesting dose selection can be based on clinical sedation needs rather than cardiac considerations
- •Overall cardiac function and valve integrity remain unaffected by dexmedetomidine sedation in healthy horses, supporting its safe use as a sedative agent
Key Findings
- •High-dose dexmedetomidine (7 µg/kg) significantly increased pulmonary artery and left atrial diameters at end-systole compared to baseline
- •Both low-dose (3.5 µg/kg) and high-dose dexmedetomidine significantly increased aortic valve diameter and left/right ventricular internal diameters at end-systole
- •Mean and maximum pulmonary velocity and pulmonary pressure gradient decreased significantly after both low and high-dose dexmedetomidine treatment
- •Dexmedetomidine sedation did not affect remaining cardiac dimensions, cardiac function measures, or valvular regurgitation